| scholarly article | Q13442814 |
| P50 | author | Hermann Einsele | Q1610986 |
| Giorgina Specchia | Q38322931 | ||
| P2093 | author name string | Ralph D Sanderson | |
| Alessandro Rambaldi | |||
| Arnon Nagler | |||
| Silvia Pace | |||
| Hila Magen | |||
| Paola Barbieri | |||
| Manik Chatterjee | |||
| Mariella Grasso | |||
| Monica Galli | |||
| Ivana Celeghini | |||
| David Paoletti | |||
| P2860 | cites work | Soluble syndecan-1 promotes growth of myeloma tumors in vivo | Q28208004 |
| SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis | Q34694466 | ||
| Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma | Q36973696 | ||
| Heparanase as a target in cancer therapy. | Q38190997 | ||
| Targeting the bone marrow microenvironment in multiple myeloma. | Q38289041 | ||
| Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma | Q38815363 | ||
| Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy | Q38985052 | ||
| Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. | Q40707545 | ||
| Chemotherapy induces expression and release of heparanase leading to changes associated with an aggressive tumor phenotype | Q41158870 | ||
| Heparanase: From basic research to therapeutic applications in cancer and inflammation | Q42587945 | ||
| Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting | Q45221614 | ||
| High heparanase activity in multiple myeloma is associated with elevated microvessel density | Q75207710 | ||
| Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis | Q79906000 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hematology | Q103824 |
| P304 | page(s) | e469-e472 | |
| P577 | publication date | 2018-04-26 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Phase I study of the heparanase inhibitor Roneparstat: an innovative approach for multiple myeloma therapy | |
| P478 | volume | 103 |
| Q61453558 | Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes⁻4 |
| Q89497261 | Cancer Metastasis: The Role of the Extracellular Matrix and the Heparan Sulfate Proteoglycan Perlecan |
| Q91646567 | Clinical applications of exosome membrane proteins |
| Q60960606 | Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases |
| Q91798106 | Forty Years of Basic and Translational Heparanase Research |
| Q99591085 | Hedgehog Signaling and Truncated GLI1 in Cancer |
| Q58585910 | Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity |
| Q89622368 | Heparanase Loosens E-Cadherin-Mediated Cell-Cell Contact via Activation of Src |
| Q60931211 | Heparanase: A Multitasking Protein Involved in Extracellular Matrix (ECM) Remodeling and Intracellular Events |
| Q59799492 | Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury |
| Q99713814 | Long-chain polyunsaturated omega-3 fatty acids reduce multiple myeloma exosome-mediated suppression of NK cell cytotoxicity |
| Q58761454 | Multiple Roles of Glycans in Hematological Malignancies |
| Q92137106 | Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds |
| Q92812032 | The Challenge of Modulating Heparan Sulfate Turnover by Multitarget Heparin Derivatives |
| Q90288843 | The multifaceted role of iron in renal health and disease |
Search more.